MTOR and osteosarcoma: Moreover, N’-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene] benzohydrazide (MDA19) was found to downregulate the expression of the main proteins involved in the EMT process, specifically PI3K/AKT/mTOR, inhibiting EMT in osteosarcoma cells (62).